Microbot Medical Dividendos y recompras

Dividendo controles de criterios 0/6

Microbot Medical no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-32.4%

Rendimiento de la recompra

Rendimiento total para el accionista	-32.4%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Dec 30

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Sep 01

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Dec 28

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

Dec 24

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Aug 27

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

May 12

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Jan 27

Microbot Medical's study of surgical robotic system meets endpoints

Jan 14

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de MBOT han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de MBOT han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Microbot Medical vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de MBOT con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (MBOT)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Medical Equipment)	1.6%
Analista de previsiones (MBOT) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de MBOT en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de MBOT en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de MBOT para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que MBOT no ha comunicado ningún pago.

Microbot Medical Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New minor risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Price target decreased by 60% to US$8.00

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Price target decreased by 58% to US$8.00

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical acquires Nitiloop, terms undisclosed

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical confirms GLP trial on track to begin later this month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022

High number of new directors

Will Microbot Medical (NASDAQ:MBOT) Spend Its Cash Wisely?

High number of new directors

Microbot Medical Inc. Announces Executive Changes

Microbot Medical's Stryker Collaboration Makes This An Intriguing High Flier

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

New 90-day high: US$9.49

Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System

New 90-day high: US$8.34